Information from the abstract
House dust mite (HDM) allergy remains one of the most prevalent allergic disorders worldwide and is a major contributor to allergic rhinitis (AR), asthma, and atopic dermatitis (AD) (1,2).Sensitization is primarily driven by exposure to allergenic proteins derived from the feces, secretions, and shed body parts of Dermatophagoides pteronyssinus and Dermatophagoides farinae, which thrive in warm and humid indoor environments (3). The resulting IgE-mediated immune response imposes a substantial global health burden and continues to rise in prevalence, particularly in rapidly urbanizing regions (4). HDM sensitization occurs in more than 50% of allergic individuals living in HDM-rich environments, with an estimated 65-130 million people worldwide experiencing HDM allergy (5) Current management of HDM allergy includes allergen avoidance, pharmacotherapy with antihistamines and corticosteroids, and allergen immunotherapy (6). Although these approaches can effectively reduce symptoms, their long-term efficacy and disease-modifying potential remain variable. On the other hand, emerging biologic therapies targeting IgE and type-2 inflammatory pathways, including omalizumab and dupilumab, offer promising alternatives for patients with severe or treatment-refractory disease (7).Beyond treatment, growing attention is being directed toward environmental interventions aimed at reducing indoor allergen exposure. Improvements in indoor air quality, humidity control, allergen-impermeable materials, and novel anti-mite technologies may complement medical management, although their effectiveness continues to be evaluated. Concurrently, advances in genomics, epigenetics, and microbiome research are revealing important interactions between genetic susceptibility and environmental exposures, opening new avenues for personalized prevention and therapeutic strategies (8). Children with coexisting atopic diseases showed higher allergen sensitization rates, indicating a greater risk of progressive allergic disease. These findings highlight the importance of regional We would like to extend our sincere appreciation to all the contributors who participated in this Research Topic. It has been a rewarding experience to co-edit such a remarkable collection of scholarly works. Despite substantial progress, significant challenges remain. Existing therapies rarely provide sustained remission, allergen avoidance is difficult to achieve in real-world settings, and patient responses vary considerably owing to immunologic and genetic heterogeneity. Future research should therefore focus on highly sensitive molecular diagnostics, biomarker-guided precision medicine, novel immunomodulatory and biologic therapies, and innovative environmental control technologies. Such advances may ultimately transform the prevention and management of HDM-associated allergic diseases and improve long-term patient outcomes.
Why this record is monitored
This record has an Impact Signal of 71/100 based on recency, source, collaboration, and bibliographic signals. It prioritizes monitoring and is not a judgment of research quality.
Related topics: Allergic Rhinitis and Sensitization · Dermatology and Skin Diseases · Asthma and respiratory diseases
Thai researcher and institutional participation
Pongsakorn Tantilipikorn · Siriraj Hospital
Data limitations
This page is a bibliographic record based on abstract-level information, not a full analysis or quality assessment. Verify the DOI and original article before citation.